logo

PGEN

Precigen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

PGEN fundamentals

Precigen (PGEN) released its earnings on Nov 13, 2025: revenue was 2.92M (YoY +206.40%), beat estimates; EPS was -1.06 (YoY -1077.78%), missed estimates.
Revenue / YoY
2.92M
+206.40%
EPS / YoY
-1.06
-1077.78%
Report date
Nov 13, 2025
PGEN Earnings Call Summary for Q3,2025
  • Breakthrough Therapy Launched: PAPZIMEOS approved for all adult RRP patients with 51% complete response rate and 3+ years surgery-free durability.
  • Commercial Momentum: 90% of target institutions engaged, 80M+ lives covered, $123.6M cash to fund 2026 breakeven.
  • Growth Catalysts: European expansion underway, pediatric trials planned, redosing supported by clinical data.
  • Financial Discipline: 15-20% gross margin, non-cash losses resolved, no recurring dilution.
EPS
Revenue

Revenue & Expenses

PGEN has released its 2025 Q3 earnings report, with revenue of 2.92M, reflecting a YoY change of 206.61%, and net profit of -146.34M, showing a YoY change of -510.33%. The Sankey diagram below clearly presents PGEN's revenue sources and cost distribution.

Key Indicators

Precigen (PGEN) key financial stats and ratios, covering profitability, financial health, and leverage.
Precigen (PGEN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Precigen (PGEN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Precigen (PGEN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Precigen (PGEN) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Precigen (PGEN) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield